Current Income Tax Expense (Benefit) of ELITE PHARMACEUTICALS INC /NV/ from 31 Mar 2023 to 31 Mar 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.
Summary
ELITE PHARMACEUTICALS INC /NV/ quarterly and annual Current Income Tax Expense (Benefit) in USD history and change rate from 31 Mar 2023 to 31 Mar 2025.
  • ELITE PHARMACEUTICALS INC /NV/ Current Income Tax Expense (Benefit) for the quarter ending 31 Mar 2025 was $1,992,399.
  • ELITE PHARMACEUTICALS INC /NV/ Current Income Tax Expense (Benefit) for the twelve months ending 31 Mar 2025 was $468,000, a 36% increase year-over-year.
  • ELITE PHARMACEUTICALS INC /NV/ annual Current Income Tax Expense (Benefit) for 2024 was $468,000, a 36% increase from 2023.
  • ELITE PHARMACEUTICALS INC /NV/ annual Current Income Tax Expense (Benefit) for 2023 was $343,000, a 19% decline from 2022.
Source SEC data
View on sec.gov
Current Income Tax Expense (Benefit), Trailing 12 Months (USD)
Current Income Tax Expense (Benefit), Quarterly (USD)
Current Income Tax Expense (Benefit), YoY Quarterly Change (%)
Current Income Tax Expense (Benefit), Annual (USD)
Current Income Tax Expense (Benefit), YoY Annual Change (%)

ELITE PHARMACEUTICALS INC /NV/ Quarterly Current Income Tax Expense (Benefit) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $468,000 $1,992,399 +$20,272,371 01 Jan 2025 31 Mar 2025 10-K 30 Jun 2025 2025 FY
Q4 2024 $19,804,371 $239,175 -$1,039,788 -130% 01 Oct 2024 31 Dec 2024 10-Q 13 Feb 2025 2025 Q3
Q3 2024 $18,764,583 $1,517,203 -$19,184,587 -109% 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2024 2025 Q2
Q2 2024 $420,004 $231,979 +$77,004 +50% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2024 2025 Q1
Q1 2024 $343,000 $18,279,972 01 Jan 2024 31 Mar 2024 10-K 30 Jun 2025 2025 FY
Q4 2023 $800,613 01 Oct 2023 31 Dec 2023 10-Q 13 Feb 2025 2025 Q3
Q3 2023 $17,667,384 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024 2025 Q2
Q2 2023 $154,975 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2024 2025 Q1

ELITE PHARMACEUTICALS INC /NV/ Annual Current Income Tax Expense (Benefit) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $468,000 +$125,000 +36% 01 Apr 2024 31 Mar 2025 10-K 30 Jun 2025 2025 FY
2023 $343,000 -$81,000 -19% 01 Apr 2023 31 Mar 2024 10-K 30 Jun 2025 2025 FY
2022 $424,000 01 Apr 2022 31 Mar 2023 10-K 01 Jul 2024 2024 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.